* Anergen Inc., of Redwood City, Calif., filed aninvestigational new drug application for a Phase I/II trialusing MS-AnergiX for multiple sclerosis.
* BioCryst Pharmaceuticals Inc., of Birmingham, Ala.,started an expanded Phase II trial with the topicalformulation of BCX-34 for psoriasis. The double-blind,placebo-controlled trial will involve 90 patients.
* GelTex Pharmaceuticals Inc., of Waltham, Mass.,completed an initial public offering of 2.5 million sharespriced at $10 each. The company is developing non-absorbed, polymer-based drugs that selectively bind toand eliminate substances from the intestinal tract.
* Immunex Corp., of Seattle, said it was served with twolawsuits from shareholders in connection with the buyoutoffer from American Home Products Corp., of Madison,N.J. Among the allegations is that the $14.50-per-sharebuyout price is too low. (See BioWorld Today, Nov. 3,1995, p. 1.)
* Innovir Laboratories Inc., of New York, entered into aresearch collaboration with The Rockefeller Center forthe preclinical evaluation of a new approach for thetreatment of various inflammatory skin conditions.
* Introgen Therapeutics Inc., of Austin, Texas, saidresearchers at the University of Texas M.D. AndersonCancer Center initiated three in vivo gene therapy studies.The first patient was injected with a p53/adenoviral genetherapy product for non-resectable and resectable headand neck cancer and non-small cell lung cancer.
* Paracelsian Inc., of Ithaca, N.Y., said it recentlycompleted the placement of a preferred convertible stockissue, which will be used for strategic acquisitions.Details of the financing were not disclosed.
* VimRx Pharmaceuticals Inc., of Stamford, Conn.,received approval to conduct trials of VIMRxyn, asynthetic version of hypericin, for the treatment of AIDSin Thailand.
(c) 1997 American Health Consultants. All rights reserved.